Noninvasive biomarker testing and risk stratification in MASLD/MASH: Laboratory options for assessing risk of liver fibrosis progression

Description

This webinar will examine the increasing prevalence of MASLD and MASH in the United States and the challenges that often lead to delayed and missed diagnoses. Attendees will gain insights into the evolving role of noninvasive blood-based biomarker testing for MASLD and MASH in supporting risk stratification and informing management decisions.

Dr. Meena Bansal of Mount Sinai Health System will share real-world perspectives on the importance of incorporating these guideline-recommended biomarker tests into diagnostic and prognostic algorithms.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Recognize the significance and growing burden of MASLD and MASH in the United States and the importance of early detection in improving patient outcomes.
• Identify the need for noninvasive biomarker testing as part of a comprehensive approach to managing patients with liver fibrosis.

Faculty

Meena Bansal, MD, FAASLD, ABOM
Professor of Medicine
Chief, Division of Liver Diseases
Director, MASLD/MASH Center of Excellence
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Meena Bansal, MD, FAASLD, ABOM
  • Honorarium: Madrigal, NOVO, Boeheringer-Ingelheim
  • Consulting Fees: The Kinetix Group, Madrigal, Pfizer, Fibronostics, NOVO Nordisk, GSK, Boston Pharma, Merck, Boeheringer-Ingelheim, CurveBio, mBIOTA, Eli Lilly
  • Grant and/or Research Support: NIH, CDC/NIOSH, Pfizer, The Kinetix Group, Petauri, Histoindex, Siemens

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation statement

This activity will be submitted for 1.0 ACCENT® continuing education credits.

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].